These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 26324762)

  • 21. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 22. Evidence for an oncogenic modifier role for mutant histone acetyltransferases in diffuse large B-cell lymphoma.
    Haery L; Mussakhan S; Waxman DJ; Gilmore TD
    Leuk Lymphoma; 2016 Nov; 57(11):2661-71. PubMed ID: 27003102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL).
    Bavi P; Uddin S; Bu R; Ahmed M; Abubaker J; Balde V; Qadri Z; Ajarim D; Al-Dayel F; Hussain AR; Al-Kuraya KS
    J Pathol; 2011 Jul; 224(3):355-66. PubMed ID: 21506127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
    Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
    J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of nuclear factor-κB regulators TNFAIP3 and CARD11 in Middle Eastern diffuse large B-cell lymphoma.
    Bu R; Bavi P; Abubaker J; Jehan Z; Al-Haqawi W; Ajarim D; Al-Dayel F; Uddin S; Al-Kuraya KS
    Leuk Lymphoma; 2012 Oct; 53(10):1971-7. PubMed ID: 22397314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.
    Shen R; Fu D; Dong L; Zhang MC; Shi Q; Shi ZY; Cheng S; Wang L; Xu PP; Zhao WL
    Signal Transduct Target Ther; 2023 Apr; 8(1):145. PubMed ID: 37032379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes.
    Feuerhake F; Kutok JL; Monti S; Chen W; LaCasce AS; Cattoretti G; Kurtin P; Pinkus GS; de Leval L; Harris NL; Savage KJ; Neuberg D; Habermann TM; Dalla-Favera R; Golub TR; Aster JC; Shipp MA
    Blood; 2005 Aug; 106(4):1392-9. PubMed ID: 15870177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma.
    Eluard B; Nuan-Aliman S; Faumont N; Collares D; Bordereaux D; Montagne A; Martins I; Cagnard N; Caly M; Taoui O; Lordello L; Lehmann-Che J; Tesson B; Martinez-Climent JA; Copie-Bergman C; Haioun C; Tilly H; Bonsang B; Vincent-Salomon A; Jais JP; Jardin F; Leroy K; Maiuri MC; Kroemer G; Molina TJ; Feuillard J; Baud V
    Blood; 2022 Jan; 139(3):384-398. PubMed ID: 34232979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile.
    Chin M; Herscovitch M; Zhang N; Waxman DJ; Gilmore TD
    Oncogene; 2009 May; 28(20):2100-11. PubMed ID: 19377508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.
    Savage KJ; Monti S; Kutok JL; Cattoretti G; Neuberg D; De Leval L; Kurtin P; Dal Cin P; Ladd C; Feuerhake F; Aguiar RC; Li S; Salles G; Berger F; Jing W; Pinkus GS; Habermann T; Dalla-Favera R; Harris NL; Aster JC; Golub TR; Shipp MA
    Blood; 2003 Dec; 102(12):3871-9. PubMed ID: 12933571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Significance of miR-155, miR-34a and miR-30a expression in diffuse large B-cell lymphoma].
    Sun GX; Cao XS; Li Q; Wang Z; Peng J; Lu CQ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Feb; 30(1):79-83. PubMed ID: 23450486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
    Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
    Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathological implications of nuclear factor κB signal pathway activation in diffuse large B-cell lymphoma.
    Zhao Q; Fu W; Jiang H; Du J; Zhang C; Xi H; Zhou F; Li R; Hou J
    Hum Pathol; 2015 Apr; 46(4):524-31. PubMed ID: 25636172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.
    Compagno M; Lim WK; Grunn A; Nandula SV; Brahmachary M; Shen Q; Bertoni F; Ponzoni M; Scandurra M; Califano A; Bhagat G; Chadburn A; Dalla-Favera R; Pasqualucci L
    Nature; 2009 Jun; 459(7247):717-21. PubMed ID: 19412164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
    Xu-Monette ZY; Møller MB; Tzankov A; Montes-Moreno S; Hu W; Manyam GC; Kristensen L; Fan L; Visco C; Dybkaer K; Chiu A; Tam W; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Wu L; Zhao X; Bueso-Ramos CE; Wang SA; Go RS; Li Y; Winter JN; Piris MA; Medeiros LJ; Young KH
    Blood; 2013 Oct; 122(15):2630-40. PubMed ID: 23982177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Mechanism and clinical significance of anti-apoptotic gene bcl-2 expression in diffuse large B-cell lymphoma].
    Zeng LP; Wen YL; Ma Y; Wang GQ; Li Y; Wang J; Xu LL; Zhang XM
    Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):377-81. PubMed ID: 21914345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways.
    Pham LV; Fu L; Tamayo AT; Bueso-Ramos C; Drakos E; Vega F; Medeiros LJ; Ford RJ
    Blood; 2011 Jan; 117(1):200-10. PubMed ID: 20889926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic impact of C-REL expression in diffuse large B-cell lymphoma.
    Curry CV; Ewton AA; Olsen RJ; Logan BR; Preti HA; Liu YC; Perkins SL; Chang CC
    J Hematop; 2009 Mar; 2(1):20-6. PubMed ID: 19669219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.
    Bognar MK; Vincendeau M; Erdmann T; Seeholzer T; Grau M; Linnemann JR; Ruland J; Scheel CH; Lenz P; Ott G; Lenz G; Hauck SM; Krappmann D
    Oncogene; 2016 Aug; 35(32):4269-81. PubMed ID: 26776161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.
    Davis RE; Brown KD; Siebenlist U; Staudt LM
    J Exp Med; 2001 Dec; 194(12):1861-74. PubMed ID: 11748286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.